Search

A study conducted by the Monell Chemical Senses Center in Philadelphia, Pennsylvania, explored the use of thiazolidinediones (TZDs) as bitter blockers for medications. The researchers tested the effectiveness of two TZDs, rosiglitazone (ROSI) and a simpler form of TZD, in reducing the bitterness of two bitter drugs, tenofovir alafenamide fumarate (TAF) and praziquantel (PRAZ). The study found that TZDs were partially effective in suppressing the bitterness of the drugs, but the effectiveness varied between individuals and different taste panels. The researchers concluded that the discovery of bitter receptor blockers could improve medication compliance. [Extracted from the article]

A report from Tufts University discusses the use of "skinny labels" in the generic drug industry as a tool to expedite entry into the market when the first patent for a brand's drug compound expires. The article reviews the law on this marketing pathway for generic competitors and examines the limitations on its use. It concludes that as long as generic manufacturers follow the essential skinny-label rules, they will not be found guilty of induced or contributory infringement. The research emphasizes the importance of generic drugs in providing broad access to clinical therapeutic agents and highlights the role of skinny labels in facilitating competition in the marketplace. [Extracted from the article]

A recent study conducted at the Mayo Clinic in Rochester, Minnesota, examined the use of remimazolam, a new ultra-short-acting benzodiazepine, for procedural sedation. The study analyzed data from 292 adult patients who received remimazolam during procedural sedation between June 2021 and December 2021. The findings showed that remimazolam offered advantages over commonly used sedation medications, with minimal impact on hemodynamics and respirations, quick recovery time, and no residual sedative effects. The study concluded that remimazolam presents a promising option for nurse procedural sedation. [Extracted from the article]

A recent study conducted at Lanzhou University in China has found that alcohol consumption can worsen the disulfiram-like reaction caused by medications that inhibit the breakdown of acetaldehyde. The study specifically focused on Ginaton, a tablet formulation of Ginkgo biloba extract commonly used for cardiovascular and nervous system health. The researchers recommend that healthcare providers educate patients about the potential adverse reactions of using Ginaton and the importance of avoiding alcohol while taking it. Patients should also disclose their alcohol consumption habits and seek medical advice before starting any medication or supplement while on Ginaton. [Extracted from the article]

A recent study conducted by researchers at Wenzhou Medical University in China explored the use of intermittent pneumatic compression (IPC) in preventing deep vein thrombosis (DVT) during laparoscopic Dixon surgery. The study involved 164 patients who were randomly assigned to one of four groups: feet, calves, thighs, or control (no IPC). The results showed that IPC applied to the feet or calves was associated with a reduced prevalence of DVT compared to the control group. However, there were no significant differences in DVT prevalence or thrombosis-related indicators on day 7 after surgery. The study suggests that IPC at the feet or calves can facilitate venous return and reduce the risk of DVT, particularly in the left extremities. [Extracted from the article]

A recent report from Tufts University discusses the negative impact of the US Supreme Court's decision on affirmative action on the physician workforce. The researchers argue that maintaining admissions of underrepresented students in medical schools is crucial for a diverse healthcare workforce. They highlight the preference of minority patients for practitioners of their own race and suggest that race-conscious admissions policies can address the shortage of minority physicians. However, they acknowledge that the recent Supreme Court decision poses challenges for medical schools in recruiting and seating minority applicants. The researchers propose strategies to achieve diversity within the scope of the law. [Extracted from the article]

A study conducted at the University of California San Diego (UCSD) examined the barriers to enrolling acutely ill newborns into a diagnostic genomic sequencing research study. The study found that speaking a language other than English or Spanish increased the likelihood of a newborn being ineligible for the study. The main reasons for not enrolling were the clinical team declining recruitment, stress, and the study intervention(s). The research concluded that regular monitoring and training can improve equitable enrollment into diagnostic genomic research, and there are opportunities at the federal level to improve access for those with limited English proficiency. [Extracted from the article]

Keywords: Taichung; Taiwan; Asia; Clinical Therapeutics; Drugs and Therapies EN Taichung Taiwan Asia Clinical Therapeutics Drugs and Therapies 1185 1185 1 10/30/23 20231103 NES 231103 2023 NOV 3 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies - Clinical Therapeutics have been presented. Keywords for this news article include: Taichung, Taiwan, Asia, Clinical Therapeutics, Drugs and Therapies, Taichung Veterans General Hospital. Funders for this research include Taichung Veterans General Hospital, Taiwan, Ministry of Science and Technology, Taiwan. [Extracted from the article]

Keywords: Salt Lake City; State:Utah; United States; North and Central America; Clinical Therapeutics; Drugs and Therapies; Genetics; Pediatrics; Risk and Prevention EN Salt Lake City State:Utah United States North and Central America Clinical Therapeutics Drugs and Therapies Genetics Pediatrics Risk and Prevention 819 819 1 10/24/23 20231027 NES 231027 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Drugs and Therapies - Clinical Therapeutics is now available. Keywords for this news article include: Salt Lake City, Utah, United States, North and Central America, Clinical Therapeutics, Drugs and Therapies, Genetics, Pediatrics, Risk and Prevention, University of Utah. Our news editors obtained a quote from the research from the University of Utah, "We conducted 26 semi-structured qualitative telephone interviews of parents with children/newborns with likely genetic conditions from two studies of clinical genome sequencing. [Extracted from the article]

Private health insurers often pay substantially higher prices for dialysis care than does Medicare, possibly due to highly concentrated dialysis-provider markets. Keywords: Houston; State:Texas; United States; North and Central America; Clinical Therapeutics; Drugs and Therapies; Dialysis; Health Policy; Health and Medicine; Legal Issues; Medicare; Medicare and Medicaid EN Houston State:Texas United States North and Central America Clinical Therapeutics Drugs and Therapies Dialysis Health Policy Health and Medicine Legal Issues Medicare Medicare and Medicaid 2762 2762 1 06/19/23 20230623 NES 230623 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health Insurance Week -- Investigators publish new report on Drugs and Therapies - Clinical Therapeutics. [Extracted from the article]